PREDICT is an online prognostication and treatment benefit tool designed to help clinicians and patients make informed decisions about treatment following breast cancer surgery.
The survival estimates, presented both with and without the benefits of adjuvant therapy (chemotherapy, hormone therapy, Herceptin), are provided for 5 and 10 years following surgery. The model was developed by a team of researchers from Cambridge led by Professor Gordon Wishart, and involved colleagues from the Cambridge Breast Unit, University of Cambridge Department of Oncology and the Eastern Cancer Information & Registration Centre.
The model is based on UK cancer registry data and in October 2011, a new version of PREDICT, including HER2 and the benefit of Trastuzumab, was launched on the PREDICT website. The current version of the model also includes KI67 status. Predict is now the most commonly used predictive model by UK breast surgeons, with over 12,000 hits a month on the website, and half of these from international visitors.